Arcturus Therapeutics Holdings Inc. (ARCT) stock
ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/303% below fair value
$8.36−0.08 (-0.95%)
Close on Nov 13, 2026Market cap $237.62MP/E –Yield –
Arcturus Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Arcturus Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -311.2%. For fiscal 2025 it was -93.0%, against -62.8% the year before. The highest annual figure on record is 5.9% in fiscal 2022.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -93.0% | −30.2 |
| FY2024 | Dec 31, 2024 | -62.8% | −15.9 |
| FY2023 | Dec 31, 2023 | -46.9% | −52.8 |
| FY2022 | Dec 31, 2022 | 5.9% | +1647.2 |
| FY2021 | Dec 31, 2021 | -1641.3% | −891.5 |
| FY2020 | Dec 31, 2020 | -749.8% | −627.1 |
| FY2019 | Dec 31, 2019 | -122.7% | +15.7 |
| FY2018 | Dec 31, 2018 | -138.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -50.2% | +46.1 |
| Q2 FY2026 | Jun 30, 2026 | -863.3% | −822.3 |
| Q1 FY2026 | Mar 31, 2026 | -1403.7% | −1346.5 |
| Q4 FY2025 | Dec 31, 2025 | -435.1% | −288.4 |
| Q3 FY2025 | Sep 30, 2025 | -96.3% | −70.5 |
| Q2 FY2025 | Jun 30, 2025 | -41.0% | +1.3 |
| Q1 FY2025 | Mar 31, 2025 | -57.3% | +22.7 |
| Q4 FY2024 | Dec 31, 2024 | -146.7% | −87.5 |
| Q3 FY2024 | Sep 30, 2024 | -25.8% | +17.0 |
| Q2 FY2024 | Jun 30, 2024 | -42.4% | +484.0 |
| Q1 FY2024 | Mar 31, 2024 | -80.0% | −98.4 |
| Q4 FY2023 | Dec 31, 2023 | -59.2% | −135.0 |
| Q3 FY2023 | Sep 30, 2023 | -42.8% | +232.5 |
| Q2 FY2023 | Jun 30, 2023 | -526.4% | −444.9 |
| Q1 FY2023 | Mar 31, 2023 | 18.4% | +979.1 |
| Q4 FY2022 | Dec 31, 2022 | 75.8% | +725.5 |
| Q3 FY2022 | Sep 30, 2022 | -275.3% | +1933.2 |
| Q2 FY2022 | Jun 30, 2022 | -81.5% | +2603.1 |
| Q1 FY2022 | Mar 31, 2022 | -960.7% | +1750.4 |
| Q4 FY2021 | Dec 31, 2021 | -649.7% | +739.1 |
| Q3 FY2021 | Sep 30, 2021 | -2208.5% | −1311.0 |
| Q2 FY2021 | Jun 30, 2021 | -2684.7% | −2252.2 |
| Q1 FY2021 | Mar 31, 2021 | -2711.1% | −2353.5 |
| Q4 FY2020 | Dec 31, 2020 | -1388.8% | −1024.4 |
| Q3 FY2020 | Sep 30, 2020 | -897.5% | −667.9 |
| Q2 FY2020 | Jun 30, 2020 | -432.5% | −426.8 |
| Q1 FY2020 | Mar 31, 2020 | -357.6% | −208.0 |
| Q4 FY2019 | Dec 31, 2019 | -364.5% | −355.1 |
| Q3 FY2019 | Sep 30, 2019 | -229.5% | −102.3 |
| Q2 FY2019 | Jun 30, 2019 | -5.6% | +416.5 |
| Q1 FY2019 | Mar 31, 2019 | -149.6% | – |
| Q4 FY2018 | Dec 31, 2018 | -9.4% | – |
| Q3 FY2018 | Sep 30, 2018 | -127.3% | – |
| Q2 FY2018 | Jun 30, 2018 | -422.1% | – |
See a number that looks wrong?